Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal EV25 in Healthy Volunteers and Influenza Challenge Participants
2024-514832-26-00Phase 2Completed
- Sponsor
- Eradivir
- Start
- Nov 2024
- Modality
- Vaccines & Immunotherapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in influenza comparing EV25 intranasal with Placebo intranasal (2 arms). Primary endpoint: Safety and tolerability of intranasal EV25 (Part I). Started Nov 2024; status: completed.
02
Drugs
EV25
03
Conditions
influenza
Beyond the preview
Go deeper on 2024-514832-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514832-26-00.